This review examines the immunologic consequences of common AML mutations—including FLT3-ITD, NPM1, DNMT3A, TP53, IDH1/2, and NRAS—and their role in remodeling the immune microenvironment. This evidence concerns the gene FLT3 and acute myeloid leukemia.